Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Guidance

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Earnings
  • General
  • Guidance
  • News

PENN Entertainment Clocks 0.8% Top-Line Growth In Q4 Hit By Severe Weather In December

By Shivani Kumaresan
February 2, 12:26 PM
PENN Entertainment Inc (NASDAQ:PENN) reported fourth-quarter FY22 sales growth of 0.8% year-on-year to $1.585 billion, marginally beating the consensus of $1.58 billion.…

PENN

Read More
1 minute read
  • Biotech
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News

Eli Lilly Posts Weaker Q4 Sales On Slower Demand For Its COVID-19 Treatment, Overshadowing Annual Guidance

By Vandana Singh
February 2, 11:36 AM
Eli Lilly And Co (NYSE:LLY) has reported Q4 sales of $7.30 billion, down 9% Y/Y, missing the consensus of $7.33…

LLY

Read More
1 minute read
  • Global
  • Guidance
  • Management
  • News

Estee Exec Says Overall Market In China Was Negative Double Digit In Q2

By Happy Mohamed
February 2, 11:12 AM
- Conf Call

EL

Read More
1 minute read
  • Biotech
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News
  • Trading Ideas

Merck Beats On Q4 earnings, Anticipates Almost 80% Decline In COVID-19 Treatment Sales In 2023

By Vandana Singh
February 2, 9:34 AM
Merck & Co Inc’s (NYSE:MRK) Q4 sales reached $13.8 billion, +2% Y/Y, beating the consensus of $13.67 billion. Excluding the…

MRK

Read More
1 minute read
  • Earnings
  • Guidance
  • News

Arrow Electronics Sees Q1 FY23 Adjusted EPS Of $4.40-$4.60 Versus Consensus Of $4.14

By Benzinga Newsdesk
February 2, 9:08 AM
The company expects Q1 sales of $8.33-$8.93 billion, compared to the consensus of $8.25 billion

ARW

Read More
1 minute read
  • Guidance
  • News

Lightspeed Sees FY23 Adj. EBITDA $(37)M

By Benzinga Newsdesk
February 2, 8:27 AM
For the full year of fiscal 2023, Lightspeed now expects an Adjusted EBITDA loss1 of approximately ($37) million, improved from previously-established outlook of

LSPD

Read More
1 minute read
  • Guidance
  • News

AMETEK Q1 Outlook: Adj. EPS $1.38 – $1.42 Vs. $1.43 Estimate; Revenue Up Mid-Single Digits

By Benzinga Newsdesk
February 2, 8:19 AM
"For the first quarter of 2023, overall sales are also expected to be up mid-single digits compared to the same period last year. Adjusted earnings in the quarter are anticipated to be in the range of $1.38 to $1.42

AME

Read More
1 minute read
  • Guidance
  • News

Broadridge Financial FY23 Revenue Growth Outlook 6% – 9% Vs. $7B Estimate

By Benzinga Newsdesk
February 2, 8:14 AM
2023 Guidance Reconciliation of Non-GAAP to GAAP Measures (Unaudited)   FY23 Recurring revenue growth (a)     Impact of

BR

Read More
1 minute read
  • Biotech
  • Earnings
  • General
  • Guidance
  • Health Care
  • News

Eli Lilly Raised FY23 Adjusted EPS Outlook from $8.10-$8.30 To $8.35 to $8.55 Versus Consensus of $8.28

By Benzinga Newsdesk
February 2, 8:12 AM
The company reaffirms 2023 sales guidance at $30.3-$30.8 billion compared to the consensus of $30.55 billion

LLY

Read More
1 minute read
  • Guidance
  • News

Estée Lauder Q3 Adj. EPS Outlook Of $0.37 and $0.47 Vs. $1.78 Estimate; Revenue Decline of 14% – 12%

By Benzinga Newsdesk
February 2, 7:56 AM
Third Quarter Fiscal 2023 Sales Outlook Reported net sales are forecasted to decrease between 14% and 12% versus the prior-year period. This range includes: A shift in the return to growth in Asia Travel Retail

EL

Posts pagination

Previous 1 … 503 504 505 … 637 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service